Anika Therapeutics

Anika Therapeutics is a Bedford, Massachusetts-based orthopedics company built on hyaluronic acid chemistry, selling joint-preservation products through both a commercial channel and an OEM channel that supplies HA raw materials and finished devices to other manufacturers. Its portfolio includes the Monovisc, Orthovisc and Cingal viscosupplement injections for osteoarthritis knee pain, the Hyalofast and Integrity regenerative scaffolds, and the Tactoset injectable bone substitute, plus non-orthopedic products such as Hyvisc for equine joint disease and Hyalobarrier anti-adhesion barriers. Anika reported third-quarter 2026 revenue of $30.6 million, up 10% year over year, with record commercial channel revenue of $14.0 million and gross margin improving to 62%; it also disclosed that the FDA found its Hyalofast pre-market approval application not approvable, primarily on clinical data, and reaffirmed 2027 total revenue growth guidance of flat to 5%. The company signed a ten-year Hyvisc distribution agreement with Boehringer Ingelheim and expects to submit a Cingal new drug application before the end of 2027.